Pfizer Inc. (PFE) reported a profit for third-quarter 2016 that declined 38 percent from last year, while quarterly revenue increased 8 percent. It narrowed certain 2016 financial guidance ranges. In addition, the company has decided to discontinue the global clinical development program for bococizumab, its investigational Proprotein Convertase Subtilisin Kexin type 9 inhibitor.
from RTT - Earnings http://ift.tt/2dYdQmi
via IFTTT
No comments:
Post a Comment